Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joaquin Duato
- Full Time Employees
- 141,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1962
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?
Bartlett & CO. Wealth Management LLC Sells 11,088 Shares of Johnson & Johnson $JNJ
Dorsey Wright & Associates Buys 8,953 Shares of Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Stock Position Cut by Clifford Swan Investment Counsel LLC
California Public Employees Retirement System Has $1.47 Billion Stock Position in Johnson & Johnson $JNJ
Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?
3 Biggest Pharma Giants: Buy, Sell or Hold?
Why Johnson & Johnson Is a Stock You Can Own Forever
12,555 Shares in Johnson & Johnson $JNJ Acquired by Forty three Eighteen Advisors LLC
Hamilton Point Investment Advisors LLC Raises Position in Johnson & Johnson $JNJ
Financiere des Professionnels Fonds d investissement inc. Trims Stock Position in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Stock Holdings Cut by Bessemer Group Inc.
Gerald Baker Financial Group LLC Purchases New Holdings in Johnson & Johnson $JNJ
Brokerages Set Johnson & Johnson (NYSE:JNJ) Price Target at $261.70
The Portfolio That Gives You a $2,000 Raise Every Year
3 Dividend Stocks That Have Survived Every Market Crash in July
Here’s the Funding It Takes to Keep Learning Forever
Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks